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Abstract. Immunization of volunteers under chloroquine prophylaxis by bites of Plasmodium falciparum sporozoite
(PfSPZ)–infected mosquitoes induces > 90% protection against controlled human malaria infection (CHMI). We studied
intradermal immunization with cryopreserved, infectious PfSPZ in volunteers taking chloroquine (PfSPZ chemopro-
phylaxis vaccine [CVac]). Vaccine groups 1 and 3 received 3× monthly immunizations with 7.5 × 104 PfSPZ. Control
groups 2 and 4 received normal saline. Groups 1 and 2 underwent CHMI (#1) by mosquito bite 60 days after the third
immunization. Groups 3 and 4 were boosted 168 days after the third immunization and underwent CHMI (#2) 137 days
later. Vaccinees (11/20, 55%) and controls (6/10, 60%) had the same percentage of mild to moderate solicited adverse
events. After CHMI #1, 8/10 vaccinees (group 1) and 5/5 controls (group 2) became parasitemic by microscopy; the
two negatives were positive by quantitative real-time polymerase chain reaction (qPCR). After CHMI #2, all vaccinees
in group 3 and controls in group 4 were parasitemic by qPCR. Vaccinees showed weak antibody and no detectable cel-
lular immune responses. Intradermal immunization with up to 3 × 105 PfSPZ-CVac was safe, but induced only minimal
immune responses and no sterile protection against Pf CHMI.
INTRODUCTION
Malaria accounted for an estimated 198 million clinical
cases and 584,000 deaths in 2013, with children under 5 years
of age in sub-Saharan Africa most severely affected.1 Signifi-
cant advances have been made in malaria control between
2000 and 2013: an expansion of malaria interventions helped
to reduce malaria incidence by 30% globally and by 34% in
Africa.1 To ensure these positive trends and maintain gains
achieved over the past decade, current control and preven-
tive measures such as artemisinin-based combination thera-
pies, rapid diagnostic tests, long-lasting insecticidal nets, and
indoor residual spraying should be supported by a highly
effective malaria vaccine. Emergence of artemisinin-resistant
malaria in southeast Asia2,3 and widespread insecticide resis-
tance in malaria transmitting anopheline mosquitoes4 further
increase this need. Combining various control and preventive
measures including large-scale vaccination will ultimately offer
the best prospect for success.
Progress in the clinical development of efficient immuniza-
tion strategies as a forerunner of an effective malaria vaccine
has been facilitated by controlled human malaria infections
(CHMIs). CHMIs involve small groups of malaria-naive
volunteers exposed to the bites of Plasmodium falciparum
sporozoite (PfSPZ)–infected laboratory-reared anopheline
mosquitoes. We have previously shown that healthy malaria-
naive volunteers can be fully protected against a CHMI by
mosquito bite with a homologous Pf strain for more than
2 years after three immunizations under chloroquine prophy-
laxis by bites from 12 to 15 PfSPZ-infected mosquitoes
at monthly intervals (chemoprophylaxis and sporozoites
[CPS]).5,6 Chloroquine kills disease-associated blood stages
but does not affect pre-erythrocytic (sporozoite or liver)
stages, which are exposed to the host’s immune system. CPS-
induced protection is mediated by immunity against pre-
erythrocytic stages.7
Although being a strong proof of concept, this protocol is
unsuitable for direct practical application as long as PfSPZ
are inoculated by mosquito bites. Sanaria Inc. (Rockville,
MD) has developed a process for manufacturing infectious,
aseptic, purified, vialed, and cryopreserved PfSPZ (Sanaria®
PfSPZ Challenge).8–13 To date, single doses of cryopreserved
PfSPZ have been administered at different doses up to 1.25 ×
105 PfSPZ in 221 human subjects by the intradermal (ID)
(N = 84), intramuscular (IM) (N = 70), intravenous (IV), or
direct venous inoculation (DVI) (N = 67) routes using a needle
and syringe to assess safety, tolerability, and infectivity.8,10–13
Here, we report the first phase I/IIb trial of CPS immuni-
zation with aseptic, purified, and cryopreserved PfSPZ,
an approach called PfSPZ-CVac (PfSPZ-chemoprophylaxis
vaccine) to assess safety, tolerability, immunogenicity, and
protection against a standard homologous CHMI with five
PfSPZ-infected mosquitoes.
MATERIALS AND METHODS
Study population. We recruited healthy male and female
subjects aged 18 to 35 years without a history of malaria,
adhering to inclusion and exclusion criteria as described previ-
ously.7 All subjects had an estimated 10-year risk of develop-
ing a cardiac event of less than 5% as estimated by the
systematic coronary evaluation system.14 Baseline ophthalmo-
logic examination revealed no abnormalities on fundoscopy
that might preclude treatment with chloroquine.
Subjects gave written informed consent before inclusion.
The trial was conducted in accordance with Good Clinical
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Practice and approved by the Central Committee for
Research Involving Human Subjects of The Netherlands
(CCMO NL39541.091.12). An Investigational New Drug
application was filed with the U.S. Food and Drug Adminis-
tration; Clinicaltrials.gov identifier: NCT01728701.
Trial design. This prospective, single center, double-blind,
randomized, placebo-controlled clinical trial was performed
at the Radboud University Medical Center (Radboudumc),
Nijmegen, The Netherlands, from September 2012 to Febru-
ary 2014. Thirty subjects were randomly assigned to four
study groups: vaccine groups 1 and 3 (each 10 subjects) and
control groups 2 and 4 (each five subjects) (Figure 1). All
groups received ID injections with either aseptic, purified,
cryopreserved, and infectious PfSPZ (PfSPZ Challenge)8 or
normal saline (NS) under chloroquine cover as described
below. Sixty days after the last immunization with PfSPZ
Challenge, groups 1 and 2 received a standard CHMI by five
mosquitoes infected with Pf NF54 SPZ.15 Protection was
defined as thick smear negative through day 21 post-CHMI.
Subsequent study procedures involving groups 3 and 4 were
dependent on the rate of protection: if ≥ 75%, groups 3 and
4 would receive CHMI with heterologous Pf NF135.C10-
infected mosquitoes16; if < 75%, groups 3 and 4 would
receive a fourth PfSPZ-CVac immunization or NS injection,
respectively, followed by homologous Pf NF54 CHMI.
PfSPZ-CVac immunizations. All subjects received stan-
dard chloroquine chemoprophylaxis for a period of 13 weeks
(91 days) as described previously.5 Of chloroquine base,
300 mg was given on days 0, 1, and 7 and weekly thereafter
through to day 91. On days 8, 36, and 64, vaccine groups
received six ID 10 μL injections (three injections in the del-
toid region of each arm) of PfSPZ Challenge, containing a
total of 7.5 × 104 PfSPZ. Controls received six ID 10 μL injec-
tions of NS in a similar manner as the vaccine groups. Vials of
PfSPZ Challenge stored in liquid nitrogen vapor phase were
thawed and diluted in phosphate-buffered saline containing
1% human serum albumin, and all subjects were injected
within 30 minutes of thawing. Because the protection thresh-
old was not met after the CHMI administered to groups 1
and 2, subjects in groups 3 and 4 received a fourth injection of
PfSPZ Challenge or NS, 168 days after the third immunization.
On days 5 and 10–14 after injections, subjects were
checked on an outpatient basis by attending physicians and
blood was drawn for thick blood smears; standard hema-
tological (full blood count, platelets and differentiation of
white blood cells) and biochemical (sodium, potassium, cre-
atinine, urea nitrogen, aspartate aminotransferase, alanine
aminotransferase, alkaline phosphatase, γ-glutamyl transfer-
ase, and total bilirubin) parameters; markers of myocardial
tissue damage, coagulation, inflammation, and hemolysis as
described previously (highly sensitive troponin T, D-dimer,
and lactate dehydrogenase)7; and retrospective assessment of
blood-stage parasitemia by quantitative real-time polymerase
chain reaction (qPCR). Additional blood samples for qPCR
measurements were provided on a voluntary basis on days
8 and 9 after the second and third immunizations. All signs
and symptoms (solicited and unsolicited) were recorded and
graded as follows: mild/grade 1 (awareness of symptoms that
were easily tolerated and did not interfere with usual daily
activity), moderate/grade 2 (discomfort that interfered with
FIGURE 1. Trial flow chart. On days 8, 36, and 64 after initiation of chloroquine chemoprophylaxis, vaccine groups 1 and 3 received injections
containing 7.5 × 104 Plasmodium falciparum sporozoites (PfSPZ), while control groups 2 and 4 received normal saline. On day 124, groups 1 and
2 underwent controlled human malaria infection (CHMI) with PfSPZ by mosquito bite. Groups 3 and 4 received additional PfSPZ injections on
day 232 and underwent CHMI on day 369. BMI = body mass index; ECG = electrocardiogram.
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or limited usual daily activity), or severe/grade 3 (disabling,
with subsequent inability to perform usual daily activity,
resulting in absence or required bed rest). Tympanic temper-
ature was measured and recorded as fever grade 1 (37.6–
38.0°C), grade 2 (> 38.0–39.0°C), or grade 3 (> 39.0°C). Cau-
sality of adverse events (AEs) was classified as not, possibly,
probably, or definitely related to the trial.
CHMI by mosquito bite. Anopheles stephensi mosquitoes
were reared at the Radboudumc insectary and infected
by feeding on cultured gametocytes of Pf N54 parasites,
according to standard procedures as described previously.17 Of
the mosquitoes used for CHMI, 100% had PfSPZs in their
salivary glands, and mosquitoes were infected with an average
of 75,800 and 98,000 PfSPZs per mosquito for CHMI #1
(groups 1 and 2) and CHMI #2 (groups 3 and 4), respectively.
Thirty-three days after the last dose of chloroquine, corre-
sponding to 60 days after the last immunization with cryo-
preserved PfSPZ, vaccine group 1 (N = 10) and control group
2 (N = 5) underwent CHMI by allowing five An. stephensi
sporozoite–infected mosquitoes to feed for 10 minutes as
described previously.15 The salivary glands of all blood-
engorged mosquitoes were dissected to confirm the presence
of PfSPZs. When necessary, feeding sessions were repeated
with fewer mosquitoes until exactly five infectious mosquitoes
had fed. Starting from day 5 after CHMI, subjects were
checked daily on an outpatient basis as described above for
PfSPZ-CVac immunizations. Blood sampling for thick smear
reading and retrospective assessment of parasitemia by qPCR
was performed once daily on days 5 and 6, twice daily on
days 7–15, once daily on days 16–21, and for 2 days after
initiation of antimalarial treatment. Antimalarial treatment,
consisting of a curative regimen of atovaquone/proguanil
(1,000/400 mg) once daily for 3 days, was initiated either as
soon as parasites were detected on a thick blood smear or
21 days after CHMI by mosquito bite for those who did not
become infected. Final follow-up visits were on days 35 and
140 after CHMI.
On day 14 after CHMI, one subject in vaccine group 1
was unblinded due to a cardiac serious AE (SAE).18 All
other subjects in groups 1 and 2 were unblinded according to
protocol 24 days after CHMI by mosquito bite.
Because of the cardiac SAE, the trial was put on hold for
64 days (March 13, 2013 to May 16, 2013) by the Safety
Monitoring Committee and the Central Committee for
Research Involving Human Subjects of The Netherlands.
New safety measures were adopted for follow-up after mos-
quito CHMI of groups 3 and 4. The endpoint of thick blood
smear positivity for diagnosis of malaria was changed to
qPCR positivity. Atovaquone/proguanil treatment was to be
initiated after 1) two consecutive positive qPCRs when tem-
perature < 38.0°C, 2) one positive qPCR in the presence of a
temperature ≥ 38.0°C, or 3) a positive thick smear prepared
upon clinical indication during an evening visit, which took
place during days 7–15. Subjects who underwent standard
vaccinations within 3 months before start of the trial or were
planning to take standard vaccinations during the trial period
up to 8 weeks after CHMI were excluded; this is because the
study subject with the SAE had received diphtheria, polio-
myelitis, tetanus, parenteral typhoid fever, and hepatitis A
and B vaccinations between the immunization period and
CHMI, and it is possible that these immunizations may have
played a role in the myocarditis.18
Study outcome parameters. The primary study outcome
was frequency and magnitude of AEs. Secondary study out-
comes included occurrence of Pf parasitemia after each
immunization and CHMI, as assessed by microscopic exami-
nation of thick blood smears and/or qPCR. Thick blood
smears were prepared and read as described previously.7
qPCR was performed as described previously19 with some
modifications. In brief, 5 μL Zap-oglobin II Lytic Reagent
(ref. no: 7501369-HA; Beckman Coulter, Brea, CA) was
added to each 0.5 mL blood sample, mixed and stored at
−80°C. After thawing samples were spiked with phocine
herpes virus (PhHV) as extraction control and DNA was
extracted by a MagnaPure LC isolation instrument (Roche,
Basel, Switzerland). Isolated DNA was resuspended in 50 μL
H2O and 5μL was used as template. For the detection of
Pf, the TaqMan MGB probe AAC AAT TGG AGG GCA
AG-FAM was used (Thermo Fisher Scientific, Waltham, MA).
For the quantification of PhHV, we used primers and probe
as described previously.20 The sensitivity of qPCR was
35 parasites/mL of whole blood. The prepatent period (by
qPCR or thick smear) was defined as the period between mos-
quito bite CHMI and the first positive qPCR (≥ 500 parasites/
mL) or thick smear result (≥ 2 unambiguous parasites). The
difference in the prepatent period assessed by qPCR com-
pared with thick smear was defined as Δ prepatency.
Immunologic analysis. Plasma and peripheral blood mono-
nuclear cells (PBMCs) were obtained from blood collected
into citrated BD (Franklin Lakes, NJ) Vacutainer CPT Cell
Preparation Tubes on the following time points: one day before
initiation of chloroquine prophylaxis (I1 − 1) for all volunteers,
the day before the third immunization (I3 − 1) and CHMI
(C − 1, 59 days after the third immunization) in groups 1 and
2, and one day before and 52 days after the fourth injection
of PfSPZ/NS injections in groups 3 and 4 (I4 − 1, I4 + 52).
Analysis of antibody responses by enzyme-linked immuno-
sorbent assay. Plasma concentrations of malaria antigen-
specific antibodies were determined against a pool of 100
sera from adults living in a highly endemic area in Tanzania
(HIT serum)5 by standardized enzyme-linked immunosor-
bent assay (ELISA). Recombinant proteins of circumsporo-
zoite protein (PfCSP) and liver stage antigen 1 (PfLSA-1)21
are expressed by sporozoites and liver stages, respectively,
while merozoite surface protein 1 recombinant protein
(PfMSP-1)22 is expressed by late liver and blood stages.23
Antibody reactivity to these antigens was determined to assess
exposure to and thus induction of immunity to the different
stages of the malaria cycle during the immunization regimen.
The 96-well polystyrene flat-bottomplates (NUNC™Maxisorp;
Thermo Fisher Scientific) were coated overnight at 4°C with
2 μg/mL of antigen, washed with phosphate-buffered saline
(PBS) and blocked for 1.5 hours at room temperature (RT)
with 150 μL of 5% milk in PBS. In all the washing steps that
followed, plates were washed with PBS + 0.05% Tween
(PBST). Serially diluted plasma samples (starting at 1:50 to
1:800 in 1% milk in PBST [sample buffer]) were incubated for
3 hours at RT in a humidified chamber. As a standard, dupli-
cates of pooled HIT serum were included on every plate in a
7-point dilution series. Reactivity for each antigen in undiluted
HIT serum was defined as 100 arbitrary units (AU). Bound
immunoglobulin G (IgG) was detected using horseradish per-
oxidase (HRP)–conjugated antihuman IgG (Thermo Fisher
Scientific) followed by TMB One Component HRP Microwell
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Substrate (Tebu Bio, Heerhugowaard, The Netherlands). The
reaction was stopped using 0.2 M H2SO4 and absorbance was
measured with a spectrophotometer plate reader at 450 nm
(Anthos 2020 ELISA plate reader, Cambridge, UK). Optical
density values were converted into AUs by four-parameter
logistic curve fit using Auditable Data Analysis and Man-
agement System for ELISA (ADAMSEL v1.1; http://www
.malariaresearch.eu/content/software).
Antibodies against PfSPZs by immunofluorescense assay.
Aseptic, purified PfSPZ suspended at 2 × 103 in 20 μL PBS
with 2% bovine serum albumin were added to Cel-Line
(Thermo Fisher Scientific) immunofluorescense assay (IFA)
slides as described before.24 Pre-immune control sera (I1 − 1)
were added at a single dilution of 1:50; the post-immune sam-
ples of 52 days after the fourth injection (I4 + 52) were added
at 2-fold dilutions starting at 1:50. Anti-PfCSP monoclonal
antibody 2A1025 was used as positive control. After incuba-
tion at 37°C for 1 hour, slides were washed and Alexa fluor
488–conjugated goat antihuman IgG (cat. no. A11013; Molec-
ular Probes, Thermo Fisher Scientific) (1:250 in 0.2% Evans
blue) was added followed by incubation at 37°C for 1 hour
and a washing step. Vectashield mounting medium (Vector
Laboratories, Burlingame, CA) was added to each well, and a
cover slip placed on the slide. Samples were assessed with an
Olympus (Shinjuku, Tokyo, Japan) BX51 fluorescence micro-
scope at ×400 magnification. The positive control was a serum
specimen from a volunteer immunized with PfSPZ vaccine
(radiation-attenuated PfSPZ) and a malaria-naive serum sample
was used as negative control.24 The endpoint titer was defined
as the last serum dilution at which fluorescence intensity was
higher than pre-immune sera. A postimmunization serum
sample was considered positive if it had fluorescence at a dilu-
tion of 1:50 or higher, and the preimmunization serum from
that volunteer was negative at 1:50.
Analysis of cellular immune responses by flow cytometry.
For the assessment of Pf-specific immune responses, in vitro
restimulation assays of PBMCs were performed as described
previously.26 In brief, cryopreserved PBMCs were thawed and
stimulated in vitro for 24 hours with glycerol-cryopreserved
schizont-stage Pf NF54–infected erythrocytes (PfRBCs) and
aseptic, purified, cryopreserved Pf NF54 SPZ prepared like
PfSPZ Challenge in the presence of antihuman CD107a
antibody (Pacific Blue, H4A3, Biolegend, San Diego, CA)
at 100 μL/well (final concentrations: 5 × 106 PBMC/mL;
10 × 106 PfRBC/well; 1.25 × 106 PfSPZ/mL). Uninfected red
blood cells (uRBCs) and medium with 1% HSA (AlbuRx 25;
CSL Behring AG, Bern, Switzerland) were used as a negative
control. For the last 4 hours, Brefeldin A (10 μg/mL; Sigma-
Aldrich, St. Louis, MO) and Monensin (2 μM; Sigma) were
added, along with PMA (50 ng/mL; Sigma) and ionomycin
(1 μg/mL; Sigma) in positive control wells. Cells were stained
with a viability marker (live/dead fixable dead cell stain
aqua; Invitrogen, Carlsbad, CA) and antibodies against CD3
(PerCp, UCHT1), interferon gamma (IFN-γ [PECy7, 4S.B3]),
and granzyme B (FITC, GB11; all Biolegend); CD4 (ECD,
SFCI12T4D11), γΔT cell receptor (PE, IMMU510; both
Beckman Coulter), CD8 (APC-H7, SK1; BD Biosciences)
and CD56 (biotin, MEM188 with eBioscience Streptavidin
eFluor 660; eBioscience, San Diego, CA).26 Intracellular
cytokine staining was performed using the Fixation and Per-
meabilization Buffer Kit (eBioscience). For every individual
subject, samples from all time points were thawed, stimulated,
and stained within the same experimental round. Flow cytom-
etry was performed on a 9-color Cyan ADP (Beckman Coulter)
and data were analyzed using FlowJo software (version 9.6.4;
Tree Star, Ashland, OR). Gating of cytokine-positive cells
was performed automatically, based on the geometric mean
fluorescent intensity of cytokine-negative PBMCs for each
subject, time point, and stimulus. Responses to uRBCs were
subtracted from the response to PfRBCs for every subject on
every time point.
Analysis of chloroquine and monodesethylchloroquine
concentrations. Plasma of volunteers in groups 1 and 2 col-
lected on the day before CHMI (C − 1) was used to assess
chloroquine and monodesethylchloroquine levels. The plasma
samples (100 μL) were precipitated by methanol (400 μL)
containing hydroxychloroquine (50 ng/mL). After mixing and
centrifugation, supernatants were diluted to half in ammonium
formate solution 20 mmol/L with formic acid (0.5% v/v), and
15 μL per sample was injected into the system. Chloroquine
and monodesethylchloroquine were separated and quantified
by liquid chromatography mass detection (TSQ Quantum
Ultra; ThermoFisher, France) using an Atlantis DC18 (100 ×
2.1 mm, 3 μm) column (Waters, France) using water/methanol
(95/5% v/v) with formic acid (0.1% v/v) as mobile phase. The
flow rate was 0.30 mL/minute and the column temperature
was kept at 25°C. Hydroxychloroquine was used as internal
standard. Data were acquired in the positive ion mode with
an electrospray ionization source. Multiple reaction monitor-
ing was used for data collection.
Statistical methods. Statistical analyses were performed
with GraphPad Prism 5 (La Jolla, CA). The difference in
AEs between two groups was calculated by unpaired Stu-
dent t test on the cumulative duration of AEs. Differences
between groups in prepatent periods by qPCR, in prepatency
between thick smear and qPCR (Δ prepatency), and in anti-
body levels were tested by the Mann–Whitney test. Differ-
ences in antibody concentrations between time points within
a group were tested by Wilcoxon signed-rank test.
RESULTS
Trial overview. Of 65 screened subjects (median age =
21 years; range = 18–27 years), 30 were included in the study
(Figure 1 and Table 1). Of these subjects under chloroquine
chemoprophylaxis (groups 1 and 3), 20 were immunized as
a single cohort by ID injection three times at 4-week inter-
vals with 7.5 × 104 cryopreserved PfSPZ, while 10 controls
(groups 2 and 4) received chloroquine chemoprophylaxis
and ID injections of NS following the same schedule. The
15 volunteers in groups 1 and 2 underwent CHMI #1 60 days
after the last immunization, corresponding to 33 days after
the last chloroquine dose. One subject in vaccine group 3
received tetanus vaccination after the third immunization
session and was later excluded based on the safety procedures
adopted for CHMI #2, because of the SAE after CHMI #1.
Another subject in group 3 was unable to continue participa-
tion for the fourth immunization because of logistical reasons.
Therefore, 13/15 subjects (8/10 in group 3; 5/5 in group 4)
received a fourth immunization of 7.5 × 104 PfSPZ at 168 days
after the third immunization (Figure 1). Five of these 13 sub-
jects were not able to participate in CHMI #2 for logistical
reasons. Altogether four subjects in each group underwent
CHMI #2 at 109 days after the last (fourth) chloroquine dose,
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corresponding to 137 days after their last injection of PfSPZ
or NS.
Safety and tolerability during PfSPZ-CVac immuniza-
tions. Immunizations were well tolerated. There were no signs
of local reactogenicity in vaccinees or controls. Of 20 PfSPZ-
CVac recipients, 11 (55%; seven in group 1 and four in
group 3) reported predominantly mild to moderate probably/
possibly associated solicited AEs (mean duration = 0.3 ±
0.5 days) beginning on days 1–33 after the first three immuni-
zations (Table 2). Six of 10 (60%) NS recipients (three in
group 2 and three in group 4) reported predominantly mild to
moderate probably/possibly associated solicited AEs (mean
duration = 0.3 ± 0.4 days) beginning on days 1 to 20 after the
first three immunizations. The other nine PfSPZ-CVac and
four NS-inoculated volunteers did not report any complaints.
There was no difference in the cumulative duration of probably/
possibly related solicited AEs per subject between vaccinees
(groups 1 and 3) and controls (groups 2 and 4) (P = 0.52).
There were no solicited AEs after the fourth PfSPZ-CVac
injection in vaccine group 3, and one mild headache in con-
trol group 4. Overall, the most commonly reported AE was
headache (6/20 [30%] vaccine subjects and 3/10 [30%] con-
trols), which occurred once in a vaccine group 3 volunteer as
the single reported grade 3 AE.
After the first PfSPZ-CVac immunization, a remarkable
unsolicited AE occurred in one subject in vaccine group 3.
Several hours after the fourth chloroquine dose, transitory
urticaria developed at multiple sites of the body lasting for
3 days (corresponding to days 5–8 after PfSPZ Challenge
injection). The subject did not receive any treatment of the
urticaria. This subject had a raised D-dimer level 2 days after
resolution of the urticaria (1,060 ng/mL, upper limits of nor-
mal being 500 ng/mL) that decreased to 520 ng/mL within the
next 4 days. The volunteer continued in the study, received
two more immunizations with PfSPZ-CVac and underwent
CHMI, but did not develop urticaria or any other indication
TABLE 2
AEs during immunizations #1–4
Adverse event*
PfSPZ-CVac groups 1† (N = 10) and 3 (N = 2†/N = 8‡) Control groups 2† (N = 5) and 4‡ (N = 5)
No. of volunteers
Mean duration ± SD
(days)
Occurrence after injections
(days) No. of volunteers
Mean duration ± SD
(days)
Occurrence after injections
(days)
Abdominal pain 2 0.9 ± 1.0 −6, 25 2 0.1 ± 0.02 1–10
Chills 2 1.1 ± 1.2 2–4, 4 N/A N/A N/A
Diarrhea 1 0.6 20 N/A N/A N/A
Headache 6 0.2 ± 0.2 −2 to 33 3 0.5 ± 0.6 1–20
Nausea 4 0.4 ± 0.6 −6 to 27 1 0.1 ± 0.1 20
Vomiting 2 0.02 ± 0.0 −1, 6 N/A N/A N/A
Any 11 0.3 ± 0.5 N/A 6 0.3 ± 0.4 N/A
AE = adverse events; N/A = not applicable; PfSPZ-CVac = Plasmodium falciparum sporozoite chemoprophylaxis vaccine; SD = standard deviation.
*Subjects could have more than one AE. Only solicited AEs that were possibly or probably related to the study are listed. Solicited AEs were fever, headache, malaise, fatigue, dizziness,
myalgia, arthralgia, nausea, vomiting, chills, diarrhea, abdominal pain, chest pain, palpitations, and shortness of breath.
†Total of three PfSPZ or normal saline immunizations.
‡Total of four PfSPZ or normal saline immunizations.
TABLE 1
Trial summary table
Group 1 Group 2 Group 3 Group 4
N = 10 N = 5 N = 10 (N = 4 received CHMI) N = 5 (N = 4 received CHMI)
Dose (number of PfSPZ) 3 × 75,000 0 3 × 75,000 (N = 2) 0
4 × 75,000 (N = 8)
Route of administration ID ID ID ID
Number of volunteers who became TS+ 8 5 N/A N/A
Listing of times to TS+ (days) 10.5, 10.5, 11, 12, 12,
14, 14.5, and 15
10.5, 10.5, 13.5,
14, and 16
N/A N/A
Geometric mean time to TS+ (days) 13.7 12.7 N/A N/A
Listing of parasite density by
qPCR at time of TS+
(parasites/μL blood)
14, 26, 13, 40, 46, 66,
24, and 27
44, 120, 75,
32, and 1
N/A N/A
Geometric mean parasite density by
qPCR at time of TS+
(parasites/μL blood)
27.9 26.3 N/A N/A
Number of volunteers who became
qPCR+
10 (100%) 5 (100%) 4 (100%) 4 (100%)
Listing of times to qPCR+ (days) 7.0, 7.0, 7.0, 7.0, 7.0,
7.0, 9.0, 10.5,
10.5, and 10.5
7.0, 7.0, 7.0,
7.0, and 10.5
7.0, 10.5, 10.5, and 10.5 7.0, 7.0, 7.0, and 10.0
Geometric mean time to qPCR+ (days) 8.1 7.6 9.5 7.7
Listing of parasite densities by
qPCR at time of qPCR+
(parasites/μL blood)
0.08, 1.01, 0.09, 0.13,
0.25, 0.07, 0.08, 0.05,
0.05, and 0.08
1,02, 0.47, 0.90,
0.13, and 1.78
0.74, 1.40, 0.08, and 0.06 0.86, 0.36, 0.97, and 0.52
Geometric mean parasite density by
qPCR at time of qPCR+
(parasites/μL blood)
0.11 0.63 0.27 0.63
CHMI = controlled human malaria infection; ID = intradermal; N/A = not applicable; PfSPZ = Plasmodium falciparum sporozoite; qPCR+ = quantitative real-time polymerase chain reaction
positive; TS+ = thick smear positive.
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of an allergic reaction. However, the D-dimer levels were
elevated after each of the three following immunizations
(range = 520–1,350 ng/mL).
None of the 20 PfSPZ-CVac recipients developed para-
sitemia during the immunization period, as detected by thick
blood smears and retrospectively by qPCR. Furthermore, lym-
phocyte and platelet counts did not decline after immunizations.
Protective efficacy after CHMI by Pf-infected mosquitoes.
All five controls in group 2 became thick smear positive.
However, this group showed a wide variation in prepatent
periods (median = 13.5 days, range = 10.5–16 days; Figure 2
and Table 1) and a median Δ prepatency (difference
between prepatent period by thick blood smear and qPCR)
of 6.5 days (range = 3.0–9.0 days), which was significantly
longer compared with previous studies7,26,27 (P = 0.006). This
wide range is explained by the prolonged parasitemia below
the detection limit for microscopy in two of the control sub-
jects (represented by the triangle and star lines in Figure 3).
Retrospective parasitemia measurement by qPCR revealed a
median prepatent period of 7.0 days (range = 7.0–10.5 days),
comparable to previous studies7,26,27 (P = 0.56).
Eight of 10 vaccinees developed patent parasitemia by
thick smear (median prepatent period by thick smear of
12 days, range = 10.5–15 days), while two subjects in group 1
remained thick smear negative throughout the 21-day follow-
up period (Figure 2). Importantly, both thick smear–negative
subjects had positive qPCRs on either day 7 post-CHMI
(85 parasites/mL) or days 7 and 7.5 (252 and 265 parasites/
mL), but then remained qPCR negative through day 21 post-
CHMI (Supplemental Figure 1). This initial prepatent period
by qPCR was in line with the other volunteers in this group
(range = 7.0–10.5 days) and similar to control group 2 (P =
0.55). On the day before CHMI (C − 1), plasma chloroquine
was deemed to be below the minimum therapeutic concentra-
tion in vivo in all 15 subjects.28 However, it is noteworthy that
both thick smear–negative subjects had higher levels of
chloroquine in plasma (13 μg/L) than all of the thick smear–
positive subjects (≤ 5 μg/L). The monodesethylchloroquine
levels (principal active metabolite of chloroquine) were not
different in these two individuals with negative thick smears
than the subjects who were thick smear positive (< 5 μg/L).
The combined data suggest that a parasite killing effect of
residual chloroquine levels cannot be excluded in the two
thick smear–negative but qPCR-positive individuals.
The second CHMI was administered to groups 3 and 4 after
a fourth immunization. All eight subjects became qPCR posi-
tive (Figure 4) with a median prepatent period of 10.5 days
(range = 7–10.5 days) in immunized volunteers (N = 4) and
7 days (range = 7–10 days) in controls (N = 4; P = 0.11,
Mann–Whitney U test, two-tailed). There were no thick smear
results to report because all subjects were treated based on
qPCR results.
AEs after CHMI by Pf-infected mosquitoes. All subjects
in groups 1 and 2 experienced solicited AEs possibly or
probably related to CHMI (mean number of AEs per sub-
ject in group 1 = 6.9, mean duration = 0.6 ± 1.2 days; group
2 = 8.4, mean duration = 0.6 ± 0.7 days), with headache
(N = 29), fever (N = 20), and nausea (N = 19) most com-
monly reported (Table 3). There was no significant differ-
ence between the cumulative duration of AEs per subject
in group 1 compared with group 2 (3.8 versus 4.7 days,
FIGURE 2. Time to parasitemia by microscopy after controlled
human malaria infection (CHMI) #1. The time to thick smear posi-
tivity is shown for 10 Plasmodium falciparum sporozoite chemopro-
phylaxis vaccine (PfSPZ-CVac) recipients (group 1, black line) and
five control subjects (group 2, gray dashed line).
FIGURE 3. Parasite dynamics by quantitative real-time polymer-
ase chain reaction (qPCR) after controlled human malaria infection
(CHMI) #1. Individual parasite density curves of control subjects
(N = 5) measured by qPCR are shown up to day of treatment, based
on diagnosis by thick smear. The gray dotted line indicates the aver-
age parasite detection limit for microscopy. Four of five subjects were
first positive on day 7. One subject was first positive on day 10.5.
FIGURE 4. Parasite dynamics by quantitative real-time polymer-
ase chain reaction (qPCR) after controlled human malaria infection
(CHMI) #2. Parasite densities are shown until the day of treatment,
based on diagnosis by quantitative polymerase chain reaction. Each line
represents a single subject: the gray lines represent subjects of vaccine
group 3 (N = 4), the black lines subjects of control group 4 (N = 4).
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respectively; P = 0.64). One SAE occurred in a subject in
vaccine group 1 on day 13 after CHMI and 2 days after ini-
tiation of treatment with atovaquone/proguanil (72 days
after last PfSPZ-CVac immunization), which was diagnosed
as acute myocarditis.18 Abnormal laboratory values normal-
ized without complications in all subjects.
All volunteers in group 3, except for one, experienced
solicited AEs possibly or probably related to CHMI (mean
number of AEs per subject in group 3 = 4.8, mean duration =
0.5 ± 0.6 days; in group 4 = 6.8, mean duration = 0.9 ±
1.9 days), with headache (N = 15), nausea (N = 9), and
chills (N = 7) as most common symptoms (Table 3). The
cumulative duration of AEs per subject in group 3 was simi-
lar to group 4 (2.3 versus 6.0 days, respectively; P = 0.051).
In addition, there was no significant difference between con-
trol groups 2 and 4 (P = 0.51), although there was a trend
toward a lower frequency of AEs in group 4 in which anti-
malarial treatment was initiated after qPCR instead of thick
smear positivity.
Humoral and cellular immune responses. First we addressed
whether volunteers immunized with PfSPZ-CVac in group 1
had specific antibodies to PfCSP, PfLSA-1, or PfMSP-1 at
59 days after the third immunization and one day before
CHMI. Antibodies to PfCSP were significantly increased com-
pared with preimmunization (P = 0.03) with fold increases in
titers ranging from 0.9 to 5.7 (median = 2.66). Five of 10 sub-
jects showed a greater than 2-fold rise of anti-PfCSP antibody
titers. Antibodies to PfLSA-1 and PfMSP-1 showed no sig-
nificant increase (Figure 5A). The increase in anti-PfCSP
antibody titers was comparable in both PfSPZ-CVac groups
(1 and 3) after the first two immunizations (P = 0.41).
The third immunization increased anti-PfCSP antibodies
in 7/10 subjects in group 1, but in only one subject more
than 2-fold (I3 − 1 versus I3 + 59; median fold increase with
range = 1.26 [0.79–2.45]; P = 0.28). In contrast, after the
fourth immunization anti-PfCSP antibodies were boosted
in 8/8 subjects of group 3 and by at least 2-fold in three
subjects (I4 − 1 versus I4 + 52; median fold increase with
range = 1.43 [1.25–5.74]; P = 0.008; Figure 5B). Similarly,
7/8 subjects of group 3 had antibodies against PfSPZ by
IFA after the fourth immunization (anti-PfSPZ titers ranged
from 50 to 400, geometric mean = 110) in contrast to con-
trols (anti-PfSPZ titer < 50). Although the proportion of
anti-PfCSP responders increased in group 3 after the fourth
dose, the magnitude of the antibody response remained similar
to the post-third dose in group 1 (P = 0.24). These data suggest
TABLE 3
AEs after mosquito CHMI
CHMI #1 PfSPZ-CVac group 1 (N = 10) Control group 2 (N = 5)
AE* No. of volunteers Mean duration ± SD (days) No. of volunteers Mean duration ± SD (days)
Abdominal pain 2 0.5 ± 0.1 2 0.1 ± 0.1
Chest pain, unspecified 1 0.0 0 N/A
Chills 6 0.2 ± 0.1 3 0.4 ± 0.2
Diarrhea 0 N/A 1 0.1 ± 0.0
Dizziness 1 1.2 2 0.1 ± 0.0
Fatigue 2 4.0 ± 5.2 1 0.4 ± 0.3
Fever 7 0.3 ± 0.3 4 0.6 ± 0.4
Headache 8 0.5 ± 0.4 5 0.9 ± 1.1
Malaise 1 0.3 1 0.5
Myalgia 2 1.2 ± 0.7 3 1.2 ± 0.7
Nausea 5 0.3 ± 0.3 3 0.3 ± 0.4
Vomiting 2 0.0 ± 0.0 1 0.2
Any 10 0.6 ± 1.2 5 0.6 ± 0.7
Grade 3 AE
Fever 3 0.2 ± 0.1 1 0.5
Headache 1 0.4 0 N/A
Nausea 0 N/A 1 0.3
Vomiting 2 0.0 ± 0.0 1 0.2
Any 4 0.1 ± 0.2 2 0.3 ± 0.2
CHMI #2 PfSPZ-CVac group 3 (N = 4) Control group 4 (N = 4)
AE No. of volunteers Mean duration ± SD (days) No. of volunteers Mean duration ± SD (days)
Abdominal pain 0 N/A 2 0.3 ± 0.2
Chills 1 0.3 2 0.0 ± 0.0
Dizziness 0 N/A 1 0.1
Fever 1 0.6 2 0.8 ± 1.0
Headache 3 0.4 ± 0.5 3 2.4 ± 3.2
Malaise 1 2.2 0 N/A
Myalgia 1 0.6 ± 0.6 1 1.5
Nausea 3 0.3 ± 0.2 2 0.2 ± 0.1
Vomiting 1 0.0 0 N/A
Any 3 0.5 ± 0.6 4 0.9 ± 1.9
Grade 3 AE
Fever 0 N/A 1 0.4
Headache 0 N/A 1 0.1
Vomiting 1 0.0 0 N/A
Any 1 0.0 1 0.3 ± 0.2
AE = adverse event; CHMI = controlled human malaria infection; N/A = not applicable; PfSPZ-CVac = Plasmodium falciparum sporozoite chemoprophylaxis vaccine; SD = standard deviation.
*Subjects could have more than one AE. Only solicited adverse events that were possibly or probably related to the study are listed.
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that four immunizations will increase the number of responders
without further increasing the specific antibody titer. Antibodies
against PfLSA-1 and PfMSP-1 did not significantly increase
after the fourth immunization (data not shown).
In contrast to humoral responses, neither IFN-γ, CD107a
nor granzyme B recall responses to PfRBC or PfSPZ, which
were found to be indicative of parasite exposure previously,26,29
were induced after three PfSPZ-CVac immunizations in any
of the T-cell subsets analyzed (vaccine group 1 versus control
group 2, data not shown). Furthermore, even after the fourth
PfSPZ-CVac immunization administered in group 3 there
were still no measurable responses to PfRBC when compared
with control group 4 or preimmunization (data not shown).
DISCUSSION
This first clinical study of PfSPZ-CVac showed that the ID
immunization regimen of up to four doses of 7.5 × 104 PfSPZ
in healthy malaria-naive volunteers was safe and well toler-
ated, but did not confer detectible cellular immune responses
and protection against a homologous CHMI. In contrast, a
three-dose CPS protocol using PfSPZ-infected mosquitoes for
immunization induces strong cellular responses and > 90%
protection against CHMI as previously shown in a number
of clinical trials.5,7,26 Dose-dependent sterile protection has
been observed with 5/10 volunteers protected after PfSPZ-
infected bites from a total of only 15 mosquitoes.26 In these
CPS studies, transient parasitemia as detected by qPCR occurs
in the majority of volunteers in particular after the first immu-
nization.5 This reflects complete liver maturation followed by
rapid chloroquine-mediated killing of blood-stage parasites.
Under these conditions, the host’s immune system is appar-
ently sufficiently exposed to a critical parasite load and broad
array of antigens for induction of protective pre-erythrocytic
immune responses.23,30
In this study, we believe that insufficient numbers of PfSPZ
migrated to and developed in the liver as supported by the weak
humoral and absent cellular immune responses against Pf anti-
gens and lack of sterile protection. CPS-induced humoral
responses have been shown to correlate with the numbers of
bites by PfSPZ-infected mosquitoes and thus with the degree
of Pf-antigen exposure.23 Here, anti-PfCSP antibody responses
after PfSPZ-CVac immunizations were comparable to responses
after CPS immunizations,23 indicating exposure to adequate
numbers of PfSPZ. However, anti-PfLSA-1 and anti-PfMSP-1
antibody responses were absent, reflecting very limited hepa-
tocyte invasion and liver-stage development. This interpreta-
tion was further supported by the absence of cellular recall
responses after PfSPZ-CVac immunizations, that is, parasite-
specific IFN-γ, CD107a, or granzyme B responses, indicative
of parasite exposure,26,29 and degranulation of CD4 T cells,
previously shown to be associated with protection.26
In this trial, PfSPZ were administered ID by needle injec-
tion suggesting that the route of administration may influ-
ence outcome. In fact, murine data show that the route of
administration of fresh and cryopreserved PfSPZ is a key
FIGURE 5. Specific antibody responses induced by immunization by Plasmodium falciparum sporozoite chemoprophylaxis vaccine (PfSPZ-
CVac). Parasite-specific plasma antibody responses are shown for vaccine group 1 (N = 10, black circles), control group 2 (N = 5, gray squares),
and vaccine group 3 (N = 8, white triangles) at the following time points: (A) 1 day before the first immunization (I1 − 1) and 59 days after the
third immunization (1 day before controlled human malaria infection [CHMI]) (C − 1); (B) 1 day before (I3 − 1) and 59 days after the third
immunization (I3 + 59) (1 day before CHMI) (C − 1) as well as 1 day before the fourth immunization (I4 − 1) and 52 days later (I4 + 52). Anti-
body responses are expressed as arbitrary units (AU) in relation to Tanzanian pooled serum (100). Each line represents a single subject. Differ-
ences were analyzed using Wilcoxon matched-pairs signed-rank test. Significant differences are indicated by * (P < 0.05) and ** (P < 0.01).
CSP = circumsporozoite protein; LSA-1 = liver stage antigen 1; MSP-1 = merozoite surface protein 1.
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determinant of successful liver infection; IV and IM injec-
tions result in significantly higher (∼50-fold and 2- to 3-fold,
respectively) liver loads compared with ID and subcutaneous
(SC) injections.31 Furthermore, Ploemen and others31 dem-
onstrated that both IM and ID routes increase liver loads
when using smaller volumes and injections at multiple sites.
Such methods approach the way anopheline mosquitoes suc-
cessfully administer SPZs: in some cases before a capillary is
found the female mosquito probes the dermal skin several
times, while injecting tiny volumes of sporozoite-containing
saliva.32 In mice, compared with ID administration, IV inocu-
lation of SPZs either radiation attenuated or in combination
with chloroquine treatment increases parasite liver loads and
augments cellular immune responses with higher protective
efficacy against an infection with Plasmodium berghei.33
A series of clinical trials have been conducted to identify
the lowest dose of PfSPZ Challenge that gives 100% infection
with a prepatent period similar to CHMI studies with the
standard regimen of five NF54-PfSPZ-infected mosquitoes,
and a clear dose response. These trials show that IV or DVI
administration is more efficient than IM, which is more effi-
cient than the ID administration, all of which is in agreement
with murine data; 100% infection has been achieved by IV and
DVI,10 IM,8,12 and ID34 administration. However, a prepatent
period of < 11.5 days and a dose response have only been
achieved by IV/DVI and IM administration and have not been
achieved by ID administration.8,10–13 As shown in murine
models, the efficiency at which PfSPZs reach the liver as
reflected by liver parasite loads is a direct result of the route
of administration. This difference between IV and ID (or SC)
administration has also been seen in human volunteers with
the protective efficacy generated by radiation attenuated,
aseptic, purified, and cryopreserved PfSPZ vaccine. Four
to six doses of 1.35 × 105 irradiated PfSPZ of PfSPZ vac-
cine administered SC or ID gave minimal immune responses
and protection,24 whereas five doses of 1.35 × 105 PfSPZ
administered IV gave excellent immune responses and 100%
protection.35 Thus, IV/DVI is the most effective and efficient
method for PfSPZ administration.
The dose of 7.5 × 104 PfSPZ-CVac administered ID in our
study was well tolerated with remarkably few AEs, most of
which were mild and occurred with the same frequency in
controls, who received only NS. However, there was a cardiac
SAE at 12 days after CHMI (59 days after the last dose of
PfSPZ Challenge) and 2 days after initiation of curative treat-
ment with atovaquone/proguanil in a subject of vaccine group
1. The subject was diagnosed as having acute myocarditis, but
the pathophysiological basis for this acute myocarditis remains
unclear and a definitive etiology could not be established.18
Interestingly, there was a discrepancy in the protection
against CHMI by mosquito bite as assessed by thick smear
and retrospective qPCR in two subjects of group 1, raising the
possibility that early parasitemias could have been limited by
residual chloroquine. Another finding suggesting an impact of
chloroquine was the significantly prolonged Δ prepatency in
control group 2 (Figure 3) compared with controls of recent
previous CHMI studies. However, it is noteworthy that in a
previous CHMI trial in which there were similar plasma con-
centrations (range < 5–14 μg/L for chloroquine and < 5 μg/L
for monodesethylchloroquine),5 all five controls became thick
smear positive between days 7 and 11 after CHMI. These
plasma concentrations were deemed to be below the minimum
therapeutic concentration in vivo based on literature (Rombo
and others28: minimum = 30 μg/L), but also because identical
blood-stage parasite multiplication kinetics were seen in con-
trol subjects compared with previous studies. This suggests that
any residual chloroquine levels had no measurable parasiticidal
effect.36,37 Thus, the reasons for the lack of development of
parasite densities detectable by thick blood smear in the two
subjects who were positive by qPCR are not understood.
In conclusion, this study shows that three to four doses of
ID administered 7.5 × 104 PfSPZ Challenge given with chloro-
quine, the PfSPZ-CVac regimen used in this trial, were well
tolerated and safe, but did not protect against a homologous
CHMI by mosquito bite. The lack of protection was almost
certainly due to suboptimal parasite exposure, as supported
by weak humoral responses and lack of T-cell responses previ-
ously shown to be associated with protection. A PfSPZ-CVac
trial using DVI may result in high-level liver stage infection
and protection.
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